Moreover, Feinstein et al. demonstrated that in around 25% of CML patients in the AP, one p53 allele was lost -e.g., by the i(17q) aberration- which was associated with the inactivation of the other allele through the loss of expression, rearrangement, or point mutation. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.